Biologics or biological drugs are obtained from living organisms, such as humans, animals, and microorganisms, using complex manufacturing processes and are administered closely under monitored conditions. They contrast with traditional non-biological drugs that are synthesized in laboratories using chemical processes without the use of biological components. Cancer, infectious diseases, and autoimmune diseases are those diseases that the bio pharmacy is used to prevent, treat, or cure. Biologics bring hope for treatments for diseases such as cancer, heart disease, Alzheimer's, diabetes, and rheumatoid arthritis. Biopharmaceuticals have a few side effects and promise targeted treatments with provisional measures for personalized medicine, but this area is still in its infancy.

Over the last few years, environmental regulations, and the importance of developing sustainable products have generated a tremendous demand for biobased lubricants or biodegradable lubricants. In the lubricant industry, bio-based lubricants are used as lubricating oils to reduce energy consumption and prolong the life of equipment/machinery. Several OEM equipment manufacturers and vendors in the mining marine, construction, and wind power industries are seeking environment-friendly products. Therefore, such environmental considerations and changes in consumer behavior have compelled lubricant manufacturers to formulate lubricants with lower environmental impact.

Understanding the structure and function of proteins is a major part of modern biotechnology. Determining 3D structures at atomic resolution assists in the elucidation of protein function, molecular docking, and structure-based drug design. Protein function relies on its structure and its interactions with other proteins. Therefore, protein structure analysis yields valuable information that can be used to infer protein function. The rising adoption of protein therapeutics coupled with continuous technological advancements in instruments and consumables related to NMR spectroscopy, X-Ray crystallography, cryo-electron microscopy, and small-angle X-Ray scattering is making headway in the growth of the global 3D protein structure analysis market.

The bioprinting technique involves the periodic arrangement of various biological materials, such as biochemicals and biocells, to fabricate tissues and organs. Several bioprinting techniques are used to generate 3D functional human constructs that mimic native tissues/organs. Different biomaterials based on carbohydrates, proteins, nucleic acids, and nanocomposites are used in bioprinting methods to create biocompatible and biodegradable scaffolds. These scaffolds promote cell adhesion and proliferation in the tissues engineered using 3D bioprinting techniques. Bioprinting methods have enabled researchers and manufacturers to mimic the natural tissue microenvironment to create advanced tissue models. Also, these methods have had an immense impact on the field of medicine and healthcare.

《密码法》、《信息安全技术信息系统密码应用基本要求》出台，2021年Q3 后等保三级系统密码改造加速。密码产品主要解决网络中身份安全、通信安全和数据安全问题。等保2.0 时代开启，要求加强通讯传输、存储过程中的数据保密性，身份认证等密码产品需求提升。《密码法》出台，等保三级系统均要进行密码国产化或新增密码系统的改造。2019 年10月《密码法》正式通过，2020 年1 月1 日起施行，要求等保三级系统均要进行密码国产化或新增密码系统的改造。2021 年3 月《信息安全技术信息系统密码应用基本要求》出台，为密码改造、密码测评指明道路，显著拉动密改需求。

国家卫健委等近日联合印发《“十四五”全民健康信息化规划》，文件围绕公卫、医院信息化建设提出一系列发展目标与行动计划，针对“互联网+医疗健康”、健康医疗大数据发展进行鼓励与引导。我们看好医疗信息化行业广阔发展空间、长远发展趋势，基础建设、创新应用有望同步夯实，我们预计头部厂商凭借长期的研发投入、产品打磨、销售能力建设有望充分受益。推荐创业慧康、卫宁健康，建议关注万达信息、嘉和美康、阿里健康、平安好医生。

2022年9月，全网主机厂APP月度活跃人数达3293.07万，环比上升2.02%；9月主机厂APP的月活人数与8月相比上升明显，原因主要在于由于9月新车销量达261万辆，其中新能源汽车销量达到70.8万辆，新能源汽车的智能网联水平整体较高，因此带动主机厂APP活跃人数上涨。

Leveraging strong R&D platforms, Innovent has built a robust pipeline of 25 clinical-stage assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 5 products, including Tyvyt (sintilimab injection, PD-1 antibody), Byvasda (bevacizumab injection), Sulinno (adalimumab injection) and Halpryza (rituximab injection) approved by the National Medicine Products Administration (NMPA) for marketing in Mainland China and IBI375 (Pemigatinib, FGFR1/2/3 inhibitor) approved by Taiwan Food and Drug Administration (TFDA), 6 assets in pivotal clinical trials, and additional 14 molecules in early clinical stage.